Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?
Cancer, 06/04/09
Bria E et al. - In a trial to quantify the magnitude of benefit of the addition of hormone treatment (HT) to exclusive radiotherapy for locally advanced prostate cancer (PCa), it was found that hormone suppression plus radiotherapy significantly decreases recurrence and mortality of pts with localized PCa, without affecting toxicity.
Methods- Event-based relative risks (RR) with 95% confidence intervals (CIs) were derived through a random-effect model.
- Differences in primary (biochemical failure and clinical progression-free survival) and secondary outcomes (cancer-specific survival, overall survival [OS], recurrence patterns, and toxicity) were explored.
- Absolute differences and numbers of pts needed to treat (NNT) were calculated.
- A heterogeneity test, a metaregression analysis with clinical predictors of outcome, and a correlation analysis for surrogate endpoints were also performed.
- 7 trials (4387 pts) were gathered.
- Hormone suppression significantly decreased both biochemical failure and clinical progression-free survival, with absolute differences of 10% and 7.7%, respectively, which translates into 10 and 13 NNT.
- Cancer-specific survival and OS were also significantly improved by the addition of HT, without significant heterogeneity, with absolute differences of 5.5% and 4.9%, respectively, which translates into 18 and 20 NNT.
- Local and distant relapse were significantly decreased by HT, by 36% and 28%, respectively, and no significant differences in toxicity were found.
- Primary and secondary efficacy outcomes were significantly correlated.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Update on oral lichen planus
Expert Review of Dermatology, 10/14/09
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Today in Nephrology/Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Vitamin D compounds for people with chronic kidney disease not requiring dialysis
Cochrane Reviews, 10/23/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


